jeudi 11 mai 2017

Onco Actu du 11 mai 2017

1. Biologie

Gene Sequencing Study Reveals Unusual Mutations in Endometriosis [Johns Hopkins]

Biologists identify key step in lung cancer evolution [MIT News]

Scientists ‘carbon date’ cancer and unearth secrets about what could help make it deadly [Institute of Cancer Research]

Century-old tumours offer rare cancer clues [Nature]

4. Dépistage, diagnostic et pronostic

Prescription history could help GPs diagnose cancer earlier [Cancer Research UK]

4.14 Dép., diag. & prono. - Thyroïde

New thyroid guidelines demonstrate why we need an independent USPSTF [HealthNewsReview]

4.5 Dép., diag. & prono. - Colorectal

Gut Check: This Smart Capsule Is Making Colon-Cancer Screening Easier To Swallow [GE]

5.10 Traitements - Essais

Collection of Patient-Reported Outcomes Feasible in Cancer Clinical Trials [NCI]

New Review Article Looks at Collaborations among Researchers, Patient Groups, and Industry [Now@NEJM]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma [BMS]

5.12.5 Immunothérapies - Pharma

Roche’s shocking Tecentriq fail raises red flag for bladder cancer rivals [FiercePharma]

The Cancer Immunotherapy Fallout from Roche's Bladder Cancer Failure [The Street]

5.12.6 Immunothérapies - AMM

Merck increases grip on its lead in lung cancer, winning approval for Keytruda/chemo combo as first-line therapy [EndPoints]

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval [The Street]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression [Merck]

U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer [Reuters]

5.2 Pharma

Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302 [Astellas]

5.3 Traitements - FDA, EMA, NICE...

Progress on science, medicines and health [EMA]

5.4 Traitements - Economie

Examining the “Drug Innovation Paradox”: Should the Length of Exclusivity Reflect the Time it Takes to Develop a Drug? [FDA Law Blog]

Drug Money [National Post] ASCO (général) - Industriels

Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting [Roche]

6. Lutte contre les cancers

Seeking a Second Opinion [Cancer Research Catalyst]

Opioids in Oncology Care [Oncology Times]

6.10 Politiques

Nick Hopkinson: Conservatism and the cancer drugs fund [BMJ Blogs]

6.11 Patients

Mark Taylor: What impact does research have? [BMJ Blogs]

6.6 Publications

Former UCLA vice-chancellor loses cancer paper for image manipulation [retraction Watch]

Science publishers try new tack to combat unauthorized paper sharing [Nature]

6.7 DMP, Big Data & applis

A Day at The Future of Artificial Intelligence and Machine Learning in Healthcare Conference [medGadget]